Abstract
We compared the effects of an ACE inhibitor, captopril, with those of a DA2-dopaminergic/α2-adrenergic receptor agonist (CHF-1024) on neuroendocrine activation and cardiac fibrosis in a model of pressure-overload hypertrophy. Interrenal aortic stenosis was performed in 89 rats, treated with CHF-1024 (0.33, 2 or 6 mg kg−1 day−1), or captopril (1 g/L). Hemodynamic variables were recorded. Cardiac and renal weights, plasma aldosterone, renin activity and urinary catecholamine excretion were measured, as well as cardiac collagen. Blood pressure was lower in stenotic animals treated with CHF-1024 compared to vehicle (161 ± 10 vs 219 ± 10 mmHg, p < 0.01), but LV weight was similar. CHF-1024 elicited a marked dose-dependent attenuation of urinary norepinephrine excretion (1.80 ± 0.18 in controls compared to 0.40 ± 0.14 μg/24 h at the highest dose, p < 0.01) and of LV perivascular fibrosis. Captopril provoked a marked hypotension, reduced cardiac and body weights, plasma aldosterone concentration, dopamine excretion and perivascular collagen. The DA2/α2 agonist CHF-1024 effectively blunts adrenergic drive and cardiac fibrosis in a rat model of pressure overload.
Similar content being viewed by others
References
Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993; 22: 6A-13A.
Ostman-Smith I. Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressureoverload in the rat. Br J Pharmacol 1995; 116:27 03-09.
V. Weinberg EO, Schoen FJ, George D, et al. Angiotensinconverting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994; 90:14 10-22.
Regan CP, Anderson PG, Bishop SP, Berecek KH. Pressureindependent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats. Am J Physiol 1997; 272:H21 31-38.
Hocher B, George I, Rebstock J, et al. Endothelin systemdependent cardiac remodeling in renovascular hypertension. Hypertension 1999; 33:8 16-22.
Rona, G. Catecholamine cardiotoxicity. J Molec Cell Cardiol 1985; 17: 291-306.
Haeusler G, Lues I, Minck KO, Schelling P, Seyfried CA. Pharmacological basis for antihypertensive therapy with a novel dopamine agonist. Eur Heart J 1992; 13:D1 29-35.
Takechi S, Nomura A, Shimoni H, et al. Recovery of cardiac norepinephrine concentration and tyrosine hydroxylase activity by the central α2-adrenoceptor agonist guanabenz in rats with aortic constriction. J Cardiovasc Pharmacol 1999; 33: 409-13.
Latini R, Masson S, Jeremic G, et al. Comparative efficacy of a DA2/α2 agonist and a β-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol 1998; 31:6 01-08.
Masson S, Masseroli M, Fiordaliso F, et al. Effects of a DA2/α2 agonist and a β1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol 1999; 34: 321-26.
Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta 1967; 18:2 67-73.
Masson S, Arosio B, Luvarà G, et al. Remodelling of cardiac extracellular matrix during β-adrenergic stimulation: up-regulation of SPARC in the myocardium of adult rats. J Molec Cell Cardiol 1998; 30:15 05-14.
Nicoletti A, Heudes D, Hinglais N, et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension 1995; 26:1 01-11.
Ratajska A, Campbell SE, Cleutjens JP, Weber KT. Angiotensin II and structural remodeling of coronary vessels in rats. J Lab Clin Med 1994: 124:4 08-15.
Chomczynski P, Sacchi N. Single-step method ofRNAIsolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:1 56-59.
Crippa G, Umile A, Carrara GC, Reyes AJ. First clinical experience with the new oral dopaminergic CHF 1035 in congestive heart failure. J Heart Failure 1995; 2: 590.
Puccini P, Zanelli U, Spinabelli D, et al. In vivo metabolism of CHF 1035, a chiral aminotetralin, in the rat. Pharmacol Res 1997; 35: 209 (Abstract).
Linz W, Schaper J, Wiemer G, Albus U, Scholkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol 1992; 107: 970-75.
Reddy DS, Singh M, Ghosh S, Ganguly NK. Role of cardiac renin-angiotensin system in the development of pressureoverload left ventricular hypertrophy in rats with abdominal aortic constriction. Molec Cell Biochem 1996: 155: 1-11.
Grimm D, Kromer EP, Bocker W, et al. Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. J Hypertens 1998; 16:13 45-55.
Berndt TJ, MacDonald A, Walikonis R, et al. Excretion of catecholamines and metabolites in response to increased dietary phosphate intake. J Lab Clin Med 1993; 122: 80-84.
Bohmann C, Schaible U, Schollmeyer P, Rump LC. Alpha(2D)-adrenoceptors modulate renal noradrenaline release in normotensive and spontaneously hypertensive rats. Eur J Pharmacol 1994; 271:2 83-92.
Heller LJ, Opsahl JA, Wernsing SE, Saxena R, Katz SA. Myocardial and plasma renin-angiotensinogen dynamics during pressure-induced cardiac hypertrophy. Am J Physiol 1998; 274:R8 49-56.
Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67:13 55-64.
Baker KA, Chernin MI, Wixson SK Aceto JF. Reninangiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990; 259:H3 24-32.
Schricker K, Hamann M, Macher A, Kramer BK, Kaissling B, Kurtz A. Effect of amlodipine on renin secretion and renin gene expression in rats. Br J Pharmacol 1996; 119:7 44-50.
Kromer EP, Riegger GAJ. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol 1988; 62:1 61-63.
Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces the regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989; 11:13 25-50.
Zierhut W, Zimmer HG, Gerdes AM. Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res 1991; 69:6 09-17.
Mohabir R, Young SD, Strosberg AM. Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal. J Cardiovasc Pharmacol 1994; 23:2 91-99.
Regan CP, Anderson PG, Bishop SP, Berecek KH. Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic-banded rats. Am J Physiol 1996; 271:H9 06-13.
Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998; 97:19 52-59.
Bhambi B, Eghbali M. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 1991; 139:11 31-42.
Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994; 23:8 69-77.
Kim S, Ohta K, Hamaguchi A, et al. AT1 receptor-mediated stimulation by angiotensin II of rat aortic fibronection gene expression in vivo. Br J Pharmacol 1994; 113:6 62-63.
Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Molec Cell Biochem 1996; 154:1 71-78.
Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-β1, fibronectin, and collagen. Am J Physiol 1992; 262:H18 61-66.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Masson, S., Chimenti, S., Salio, M. et al. CHF-1024, A DA2/α2 Agonist, Blunts Norepinephrine Excretion and Cardiac Fibrosis in Pressure Overload. Cardiovasc Drugs Ther 15, 131–138 (2001). https://doi.org/10.1023/A:1011170812267
Issue Date:
DOI: https://doi.org/10.1023/A:1011170812267